Clinical value of targeted arterial infusion of ginkgo biloba extract combined with urokinase in thromboangiitis obliterans

OBJECTIVE: To investigate the clinical efficacy and safety of targeted artery infusion of Ginkgo biloba extract (GBE) combined with urokinase (URK) for treatment of thromboangiitis obliterans (TAO), and to provide a reference for the optimized treatment of TAO. METHODS: A total of 108 male TAO patients (December 2021-December 2023) were retrospectively enrolled and divided into a GBE group (54 cases, single GBE infusion) and a GBE-URK group (54 cases, GBE+URK infusion) after propensity score matching. Both groups received 72-hour continuous infusion, followed by standardized adjuvant therapy and 12-month follow-up. Key indices (pain, hemodynamics, inflammation) and safety/recurrence were compared. RESULTS: At 90 days, the GBE-URK group had lower FPS-R scores (1.89±0.84 vs 2.74±0.48, P